Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.

Front Oncol · 2020 · PMC7575747 · PMID 33117701

Europe PMC DOI

hedged sentence

0.3170

closest p · 6.3× alpha

0.3170

boldest claim

The sentences

showed a trendp = 0.317not close (p > 0.1)

The nivolumab cohort showed a trend toward better OS with no OS event compared with the others without nivolumab (median OS; not reached vs. 27.4 months) [(95% CI, 21.2–not reached), p = 0.317].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.